MX357018B - Método de diagnóstico temprano de carcinoma hepatocelular. - Google Patents

Método de diagnóstico temprano de carcinoma hepatocelular.

Info

Publication number
MX357018B
MX357018B MX2013015064A MX2013015064A MX357018B MX 357018 B MX357018 B MX 357018B MX 2013015064 A MX2013015064 A MX 2013015064A MX 2013015064 A MX2013015064 A MX 2013015064A MX 357018 B MX357018 B MX 357018B
Authority
MX
Mexico
Prior art keywords
hepatocellular carcinoma
early diagnosis
ptgr1
chc
new methods
Prior art date
Application number
MX2013015064A
Other languages
English (en)
Other versions
MX2013015064A (es
Inventor
Isael Pérez Carreón Julio
Sánchez Rodríguez Ricardo
Original Assignee
Instituto Nac De Medicina Genomica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Nac De Medicina Genomica filed Critical Instituto Nac De Medicina Genomica
Priority to MX2013015064A priority Critical patent/MX357018B/es
Priority to PCT/MX2014/000207 priority patent/WO2015093932A1/es
Publication of MX2013015064A publication Critical patent/MX2013015064A/es
Publication of MX357018B publication Critical patent/MX357018B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90206—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención provee nuevos métodos de diagnóstico temprano del carcinoma hepatocelular (CHC) mediante la detección de los productos génicos (ARNm o proteína) de la prostaglandina reductasa 1 (Ptgr1) en muestras biológicas y nuevos métodos para determinar si un paciente con CHC es candidato para ser tratado con compuestos antitumorales que sean bioactivados por la Ptgr1.
MX2013015064A 2013-12-18 2013-12-18 Método de diagnóstico temprano de carcinoma hepatocelular. MX357018B (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2013015064A MX357018B (es) 2013-12-18 2013-12-18 Método de diagnóstico temprano de carcinoma hepatocelular.
PCT/MX2014/000207 WO2015093932A1 (es) 2013-12-18 2014-12-16 Método de diagnóstico temprano de carcinoma hepatocelular

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013015064A MX357018B (es) 2013-12-18 2013-12-18 Método de diagnóstico temprano de carcinoma hepatocelular.

Publications (2)

Publication Number Publication Date
MX2013015064A MX2013015064A (es) 2015-06-18
MX357018B true MX357018B (es) 2018-06-05

Family

ID=53403172

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015064A MX357018B (es) 2013-12-18 2013-12-18 Método de diagnóstico temprano de carcinoma hepatocelular.

Country Status (2)

Country Link
MX (1) MX357018B (es)
WO (1) WO2015093932A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107663539B (zh) * 2017-09-29 2020-12-01 中山大学附属第三医院 环状RNA circ-PTGR1的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
DE10136273A1 (de) * 2001-07-25 2003-02-13 Sabine Debuschewitz Molekulare Marker beim hepatozellulären Karzinom
EP2299268A3 (en) * 2002-07-03 2011-06-15 Illumigen Biosciences Inc. Methods and compositions for diagnosing hepatocellular carcinoma
JP2006526405A (ja) * 2003-06-04 2006-11-24 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 示差的調節された肝細胞癌遺伝子およびその利用
ES2324128A1 (es) * 2005-09-29 2009-07-30 Proyecto De Biomedicina Cima, S.L. Metodo para el diagnostico de carcinoma hepatocelular mediante el empleo de marcadores moleculares.
EP2412805B1 (en) * 2006-06-09 2014-04-30 Kabushiki Kaisha Yakult Honsha Gene involved in immortalization of human cancer cell and use thereof
WO2013190075A2 (en) * 2012-06-20 2013-12-27 Meyer Helmut E Specific biomarkers for hepatocellular carcinoma (hcc)

Also Published As

Publication number Publication date
WO2015093932A1 (es) 2015-06-25
MX2013015064A (es) 2015-06-18

Similar Documents

Publication Publication Date Title
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
LT3198033T (lt) Fgfr mutantinių genų rinkinių panaudojimas identifikuojant vėžiu sergančius pacientus, kurie reaguos į gydymą fgfr inhibitoriumi
EA201890512A1 (ru) Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
EA201790398A1 (ru) Способы лечения заболевания печени
BR112016029634A2 (pt) kit, dispositivo e método para a detecção de câncer de fígado
BR112016029583A2 (pt) ?kit ou dispositivo para a detecção de câncer esofágico e método de detecção?
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
MX368099B (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
BR112016002668A2 (pt) métodos e kits para prognosticar o risco de ter uma doença ou evento cardiovasculares
IL245936A0 (en) Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers
MX384423B (es) Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2).
SV2017005459A (es) Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr
BR112017006593A2 (pt) método para detectar câncer de ovário
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
BR112018075303A2 (pt) resumo método para tratar uma doença ou condição inflamatória, e método de redução ou inibição de uma resposta imune
EA201401201A1 (ru) Способ

Legal Events

Date Code Title Description
FG Grant or registration